
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington - Tighter restrictions on Accutane could have a reverse effect - increased black market activity - the FDA told a congressional investigative subcommittee on Dec. 11.






